CuraVac   Report issue

For profit Phase 3
Founded: Rixensart Belgium (2002)
Status: Left NME R&D (2022)

Organization Overview

First Clinical Trial
2016
NCT02609022
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

cv-mg01 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Muscle Weakness (Phase 3)

Myasthenia Gravis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 1